PARLIAMENTARY WRITTEN QUESTION
Nusinersen (29 November 2017)
Question Asked
To ask the Secretary of State for Health, what the timetable is for NICE to begin its evaluation of the spinal muscular atrophy treatment Spinraza.
Asked by:
Alberto Costa (Conservative)
Asked by:
Alberto Costa (Conservative)
Answer
The National Institute for Health and Care Excellence (NICE) has been asked to develop technology appraisal guidance on the use of nusinersen (Spinraza) to treat spinal muscular atrophy and this topic has been scheduled into NICE’s work programme. The appraisal process is anticipated to begin in January 2018 and the deadline for an evidence submission is anticipated to be March 2018. Although no further details about timescales for the development of guidance are available at this stage, NICE take approximately nine months to develop guidance on a new drug depending on the individual product.
Answered by:
Steve Brine (Conservative)
7 December 2017
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.